Dostarlimab
Mesothelioma
University of Turin, Italymonoclonal_antibodyPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
56 Active assets in the Mesothelioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | BB |
Fludarabine National Cancer Institute (NCI) | Phase 2 | B |
Nivolumab Orion Corporation, Orion Pharma | Phase 2 | B |
Pembrolizumab Genmab | Phase 2 | B |
18f-fspg Andrei Iagaru | Phase 2 | B |
View all 50 →
Same molecule, other indications
Dostarlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →